Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Blood (2024) 144 (Supplement 1): 891.

https://doi.org/10.1182/blood-2024-205077

Published: 2024

Journal Articles

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Cindy Varga, Myra Robinson, Vikas Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Shanice Borden, Christopher Ferreri, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2024-204388

Published: 2024

Journal Articles

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 931.

https://doi.org/10.1182/blood-2024-202017

Published: 2024

Journal Articles

Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution

Cindy Varga, Ferdous Ahmed, Marvin Knight, Manisha Bhutani, Barry Paul, Shebli Atrash, Peter M. Voorhees, Christopher Ferreri

Blood (2024) 144 (Supplement 1): 4720.

https://doi.org/10.1182/blood-2024-204361

Published: 2024

Journal Articles

Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

Barry Paul, Myra Robinson, James Symanowski, David M Foureau, Sarah Norek, Manisha Bhutani, Christopher Ferreri, Ami P Ndiaye, Jordan Robinson, Shebli Atrash, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, April Smith, Jessica Duda, Lance Cooper, Amani Kitali, Peter M. Voorhees

Blood (2024) 144 (Supplement 1): 7027.

https://doi.org/10.1182/blood-2024-208830

Published: 2024

Journal Articles

The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research

Anas Zayad, Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Evguenia Ouchveridze, Forat Lutfi, Joseph P. McGuirk, Al-Ola Abdallah, Faiz Anwer, Manisha Bhutani, Shebli Atrash

Blood (2024) 144 (Supplement 1): 7595.

https://doi.org/10.1182/blood-2024-205422

Published: 2024

Journal Articles

Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center

Semegne Hiruy, Myra Robinson, Shebli Atrash, Barry Paul, Reed Friend, Cindy Varga, Christopher J Ferreri, Mauricio Pineda-Roman, Peter M. Voorhees, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 3769.

https://doi.org/10.1182/blood-2024-202137

Published: 2024

Journal Articles

Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study

Blood (2024) 144 (Supplement 1): 4734.

https://doi.org/10.1182/blood-2024-200344

Published: 2024

Journal Articles

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Blood (2024) 144 (Supplement 1): 594.

https://doi.org/10.1182/blood-2024-200300

Published: 2024

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2024-200958

Published: 2024

Journal Articles

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

Darryl Chang, Alma Habib, Andrew Vegel, Emily Struble, Hira Shaikh, Christopher Strouse, Kimberly M Green, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Hamza Hashmi, Joseph P. McGuirk, Abdullah Mohammad Khan, Al-Ola Abdallah, Nausheen Ahmed, Shebli Atrash, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 2404.

https://doi.org/10.1182/blood-2024-208692

Published: 2024

Journal Articles

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Morie A. Gertz, Heather J. Landau, Vaishali Sanchorawala, Manisha Bhutani, Jeffrey A. Zonder, Michael Rosenzweig, Gray Magee, Cynthia Campos, Irina Yermilov, Eunice Chang, Michael S. Broder, Preeti Bajaj

Blood (2024) 144 (Supplement 1): 3665.

https://doi.org/10.1182/blood-2024-206132

Published: 2024

Journal Articles

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Blood (2024) 144 (Supplement 1): 3792.5.

https://doi.org/10.1182/blood-2024-210957

Published: 2024

Journal Articles

Supportive Care Utilization in Patients with Multiple Myeloma-a Single Center Retrospective Study

Darryl Chang, Myra Robinson, Rupali Bose, Hamid Ehsan, Arunkumar Krishnan, Shanice Borden, Peter M. Voorhees, Barry Paul, Manisha Bhutani, Cindy Varga, Christopher Ferreri, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2024-209358

Published: 2024

Journal Articles

Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions

David M Foureau, Oscar Berlanga, Cindy Varga, Barry Paul, Shebli Atrash, Christopher Ferreri, Semegne Hiruy, Lawrence J. Druhan, Ariel Bell, Phillip Holmes-Snowden, Gabriella Lakos, Peter M. Voorhees, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 1964.

https://doi.org/10.1182/blood-2024-208695

Published: 2024

Journal Articles

Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy

Shebli Atrash, James Symanowski, Sarah Norek, Monica Plott, Cecilia Flynn, Kelly Bumgarner, Darynne Rhinehardt, Xhevahire Begic, Robin Cox, Barry Paul, Cindy Varga, Reed Friend, Christopher Ferreri, Manisha Bhutani, Mauricio Pineda-Roman, Peter M. Voorhees

Blood (2024) 144 (Supplement 1): 4751.

https://doi.org/10.1182/blood-2024-205957

Published: 2024

Journal Articles

Rural-Urban and Racial Trends in Survival of Patients with Multiple Myeloma: 1975-2019 Surveillance, Epidemiology, and End Results (SEER) Analysis

Semaje Testamark, Allison Verbyla, Myra Robinson, Peter M. Voorhees, Manisha Bhutani

Blood (2023) 142 (Supplement 1): 1977.

https://doi.org/10.1182/blood-2023-175032

Published: 2023

Journal Articles

Assessment of Incidence of Distress and Utilization of Supportive Care Services in Multiple Myeloma Patients, a Retrospective Single Center Experience

Hamid Ehsan, Myra Robinson, Patrick Meadors, Rushil Patel, Shanice Borden, Peter M. Voorhees, Delcan Walsh, Barry Paul, Manisha Bhutani, Cindy Varga, Shebli Atrash

Blood (2023) 142 (Supplement 1): 7416.

https://doi.org/10.1182/blood-2023-178114

Published: 2023

Journal Articles

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Manisha Bhutani, Myra Robinson, Shebli Atrash, Barry Paul, Mauricio Pineda-Roman, David Foureau, Cindy Varga, Reed Friend, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B Anderson, James Symanowski, Peter M. Voorhees, Saad Z Usmani

Blood (2023) 142 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2023-174972

Published: 2023

Journal Articles

Patterns of Outpatient IVIG Use before and during the COVID Pandemic in Patients with Multiple Myeloma

Jonathan Lambird, John T Mckay, Meng-Yun Lin, Lindsey Abdelfattah, Manisha Bhutani, Barry Paul, Peter M. Voorhees, Cindy Varga, Shebli Atrash, David Duane Hurd

Blood (2023) 142 (Supplement 1): 6634.

https://doi.org/10.1182/blood-2023-180345

Published: 2023

NARROW

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution

Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

The Scope of Academic and Industry Sponsorship in Shaping the Future of AL Amyloidosis Research

Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center

Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Supportive Care Utilization in Patients with Multiple Myeloma-a Single Center Retrospective Study

Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions

Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy

Rural-Urban and Racial Trends in Survival of Patients with Multiple Myeloma: 1975-2019 Surveillance, Epidemiology, and End Results (SEER) Analysis

Assessment of Incidence of Distress and Utilization of Supportive Care Services in Multiple Myeloma Patients, a Retrospective Single Center Experience

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Patterns of Outpatient IVIG Use before and during the COVID Pandemic in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only